| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2021: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2020: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2019: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2018: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
|---|
| Outline of Final Research Achievements |
In a screening of 114 compounds involved in the phenomenon of myoblast fusion using the myoblast fusion assay system (HiMy assay), drug A was found as a potential hit compound that could promote myogenic differentiation of C2C12 mouse myoblasts.There was a trend toward increased skeletal muscle weight in the groups of carcinoma-bearing mice treated with aerobic exercise or aerobic exercise plus Drug A. In particular, there was a significant increase in adiponectin expression in the group treated with aerobic exercise plus Drug A. Clinical studies showed that the amount of physical activity had an impact on postoperative complication rates and postoperative recovery in perioperative cancer patients. The study also showed that exercise therapy significantly improved physical function up to 4 weeks later in terminal cancer patients.
|
